Molly C. Li

State Key Laboratory Of Translational Oncology
Hong Kong, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Same tumor, different lungs: How chronic obstructive pulmonary disease and interstitial lung disease reshape lung cancer risk and treatment.

Same tumor, different lungs: How chronic obstructive pulmonary disease and interstitial lung disease reshape lung cancer risk and treatment.

Journal: Journal of translational internal medicine

Published: August 27, 2026

Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.

Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 03, 2026

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Journal: Cancer treatment reviews

Published: March 06, 2026

Targeting MET in EGFR-Mutated NSCLC.

Targeting MET in EGFR-Mutated NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 23, 2026

Clinical and translational roles of circulating tumor cells in non-small cell and small cell lung cancer: a narrative review.

Clinical and translational roles of circulating tumor cells in non-small cell and small cell lung cancer: a narrative review.

Journal: Journal of thoracic disease

Published: January 05, 2026

Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?

Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?

Journal: Cancer treatment reviews

Published: October 26, 2025

Optimal duration of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a systematic review and meta-analysis.

Optimal duration of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a systematic review and meta-analysis.

Journal: Journal of thoracic disease

Published: July 09, 2025

Response to the Letter to the Editor on "CNS Outcomes of Osimertinib Plus Chemotherapy in Patients with EGFR Mutation-Positive Lung Cancer Beyond Osimertinib Progression".

Response to the Letter to the Editor on "CNS Outcomes of Osimertinib Plus Chemotherapy in Patients with EGFR Mutation-Positive Lung Cancer Beyond Osimertinib Progression".

Journal: Clinical lung cancer

Published: June 13, 2025

p53 aberrant expression is pervasive in pleomorphic carcinomas of the lung and a sensitive diagnostic adjunct for biopsy specimens.

p53 aberrant expression is pervasive in pleomorphic carcinomas of the lung and a sensitive diagnostic adjunct for biopsy specimens.

Journal: Diagnostic pathology

Published: April 18, 2025

Distant Cousins From the Same Family-Understanding Uncommon EGFR Mutations.

Distant Cousins From the Same Family-Understanding Uncommon EGFR Mutations.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 09, 2025

EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN TREATING CHOROIDAL METASTASIS FROM NON-SMALL-CELL LUNG CANCER: A 10-Year Review.

EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN TREATING CHOROIDAL METASTASIS FROM NON-SMALL-CELL LUNG CANCER: A 10-Year Review.

Journal: Retina (Philadelphia, Pa.)

Published: November 06, 2024

Can therapeutic drug monitoring of lorlatinib help us design the right CROWN?

Can therapeutic drug monitoring of lorlatinib help us design the right CROWN?

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 29, 2024

Showing 1-12 of 27

Last Updated: 09/26/2026